This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/pubchem-compound/
n22http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/mixture/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/chebi/
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00304/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00304
rdf:type
n3:Drug
n3:description
A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents. [PubChem]
n3:generalReferences
# Korhonen T, Tolonen A, Uusitalo J, Lundgren S, Jalonen J, Laine K: The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15963096 # Gentile DM, Verhoeven CH, Shimada T, Back DJ: The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9864282
n3:group
approved
n3:halfLife
27.8±7.2 hours
n3:indication
For the prevention of pregnancy in women who elect to use this product as a method of contraception.
owl:sameAs
n11:DB00304 n27:DB00304
dcterms:title
Desogestrel
adms:identifier
n9:Desogestrel n13:46505739 n14:PA449238 n17:40973 n18:C07629 n19:D02367 n20:DB00304 n21:4453 n23:37400
n3:mechanismOfAction
Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like desogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.
n3:packager
n22:271B4EBE-363D-11E5-9242-09173F13E4C5
n3:synonym
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol Desogestrelum Cerazette
n3:toxicity
Symptoms of overdose include nausea and vaginal bleeding.
n3:mixture
n26:271B4EBC-363D-11E5-9242-09173F13E4C5 n26:271B4EBD-363D-11E5-9242-09173F13E4C5 n26:271B4EBA-363D-11E5-9242-09173F13E4C5 n26:271B4EBB-363D-11E5-9242-09173F13E4C5 n26:271B4EB8-363D-11E5-9242-09173F13E4C5 n26:271B4EB9-363D-11E5-9242-09173F13E4C5 n26:271B4EB6-363D-11E5-9242-09173F13E4C5 n26:271B4EB7-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
98.3%
n3:synthesisReference
Klaus Nickisch, "METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL." U.S. Patent US20130123523, issued May 16, 2013.
n24:hasConcept
n25:M0026028
foaf:page
n16:desest.htm
n3:IUPAC-Name
n4:271B4EC8-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4ECE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4ECD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4ECA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4ECB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4ECC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4EC6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4EC4-363D-11E5-9242-09173F13E4C5 n4:271B4EC7-363D-11E5-9242-09173F13E4C5 n4:271B4EDF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4EC5-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:G03AC09
n3:H-Bond-Acceptor-Count
n4:271B4ED4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4ED5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4ECF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4ED0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4ED2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4ED1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4ED3-363D-11E5-9242-09173F13E4C5
n3:absorption
Following oral administration, the relative bioavailability of desogestrel, as measured by serum levels of etonogestrel, is approximately 84%. The absolute oral bioavailability is about 76%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
54024-22-5
n3:category
n3:containedIn
n12:271B4EBF-363D-11E5-9242-09173F13E4C5 n12:271B4EC0-363D-11E5-9242-09173F13E4C5 n12:271B4EC3-363D-11E5-9242-09173F13E4C5 n12:271B4EC1-363D-11E5-9242-09173F13E4C5 n12:271B4EC2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4EDA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4EDC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4EDD-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4EDE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4ED9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4ED8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4EDB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4EC9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4ED6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4ED7-363D-11E5-9242-09173F13E4C5